Canada Pension Plan Investment Board purchased a new stake in GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 62,700 shares of the company's stock, valued at approximately $292,000.
Several other hedge funds and other institutional investors also recently made changes to their positions in GDRX. Barclays PLC grew its position in shares of GoodRx by 1,316.1% in the third quarter. Barclays PLC now owns 140,113 shares of the company's stock valued at $973,000 after purchasing an additional 130,219 shares during the last quarter. Geode Capital Management LLC grew its position in GoodRx by 6.3% during the third quarter. Geode Capital Management LLC now owns 982,729 shares of the company's stock worth $6,823,000 after buying an additional 58,610 shares in the last quarter. Sanctuary Advisors LLC acquired a new stake in GoodRx during the third quarter worth about $85,000. Franklin Resources Inc. acquired a new stake in GoodRx during the third quarter worth about $5,675,000. Finally, JPMorgan Chase & Co. grew its position in GoodRx by 358.7% during the third quarter. JPMorgan Chase & Co. now owns 24,293 shares of the company's stock worth $169,000 after buying an additional 18,997 shares in the last quarter. 63.77% of the stock is owned by institutional investors and hedge funds.
GoodRx Trading Down 0.4 %
NASDAQ GDRX traded down $0.02 on Wednesday, reaching $4.64. The company had a trading volume of 377,520 shares, compared to its average volume of 1,374,914. GoodRx Holdings, Inc. has a 52 week low of $3.82 and a 52 week high of $9.26. The stock's 50 day moving average is $4.56 and its 200-day moving average is $4.87. The company has a quick ratio of 5.48, a current ratio of 5.48 and a debt-to-equity ratio of 0.70. The stock has a market cap of $1.78 billion, a price-to-earnings ratio of -154.67, a PEG ratio of 2.46 and a beta of 1.25.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on GDRX shares. Wells Fargo & Company decreased their price objective on GoodRx from $8.00 to $7.00 and set an "overweight" rating on the stock in a report on Tuesday. KeyCorp decreased their price objective on GoodRx from $7.00 to $6.00 and set an "overweight" rating on the stock in a report on Wednesday, January 8th. Citigroup decreased their price objective on GoodRx from $7.00 to $6.25 and set a "buy" rating on the stock in a report on Friday, January 10th. Finally, Truist Financial decreased their price objective on GoodRx from $6.50 to $5.50 and set a "hold" rating on the stock in a report on Thursday, April 10th. Four investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $7.84.
View Our Latest Report on GoodRx
About GoodRx
(
Free Report)
GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.
Featured Articles

Before you consider GoodRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GoodRx wasn't on the list.
While GoodRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.